Tobacco Use for Diabetics

Agriculture currently produces the rapid development of molecular biotechnology, which can offer a cheaper way than the manufacture of vaccines and traditional medicine through the factory. Scientists have found that healthy tobacco after modifying genetic factors. Tobacco can be used to treat type 1 diabetes.

European researchers say has produced tobacco that contain anti-inflammatory compounds (anti-inflammatory) called interleukin-10 (IL-10) which can help patients with type 1 diabetes who are insulin dependent. A number of agricultural chemical companies, including Bayer and Syngenta, have been looking for ways to make complex proteins in medicinal plants, although requiring a slow process.

At present, most drugs and vaccines produced via cell culture and tissue culture. However, Mario Pezzotti of the University of Verona, who led the study of tobacco published in the journal BMC Biotechnology, believe that the tobacco plants grow more efficiently since the world has a lower cost to produce protein drugs.

Various types of plants have been studied by a number of scientists around the world, but tobacco is the most popular crop in terms of research. "Tobacco is a plant that's fantastic because it is easy to transform genetically and can easily learn the whole plant from single cells," said Pezzotti. Group work and put the interests of the tobacco giant, which is Philip Morris, which supports plant-based medicine conference

Pezzotti and colleagues - who received funding for his research from the European Union - are now planning to megujicobakan these plants to mice that have an autoimmune disease to determine its response.

Next, they wanted to test whether the repetition of small doses can help prevent diabetes in people, when given in conjunction with other compounds of glutamic acid decarboxylase, which has also been produced in tobacco plants.

Diamyd, biotechnology companies in Sweden have tested the conventional vaccine against glutamic acid decarboxylase in diabetic patients during clinical trials. The field of molecular farming has not produced the first commercial product, although Israel Protalix BioTherapeutics has conducted clinical trials on advanced enzymes for the treatment of Gaucher disease generated through a carrot cell culture. Protalix plans to submit the drug for approval from the United States and Israel.